AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management
US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...
Auto-immune
Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical unit, Janssen, has presented real-world efficacy data for...
Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...
Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US
Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...
AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues
AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year...
Everest Medicines’ Nefecon Receives First Regional NDA Approval in Macau for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that its New Drug Application (NDA) for Nefecon,...
Eli Lilly’s Omvoh Receives FDA Approval for Ulcerative Colitis Treatment
The US Food and Drug Administration (FDA) has granted regulatory approval to Eli Lilly (NYSE:...
AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment
AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at...
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...
BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment
The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers...
Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA
Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...
Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...
AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study
AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...
Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...
Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development
Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the...
Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...
Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline
Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced receiving...